PPARs as Drug Targets to Modulate Inflammatory Responses?

Author(s): Raphael Genolet, Walter Wahli, Liliane Michalik.

Journal Name: Current Drug Targets - Inflammation & Allergy
Continued as Inflammation & Allergy - Drug Targets

Volume 3 , Issue 4 , 2004

Abstract:

The three peroxisome proliferator-activated receptors (PPARs) isotypes (PPARα, β / δ and γ) belong to the nuclear hormone receptor family. During the last decade, they have been identified as anti-inflammatory transcription factors. Part of this regulation antiinflammatory is mediated through negative interference between PPARs and other nuclear factors such as NFκB, AP-1 and C / EBP, which regulate innate as well as adaptative immunity. In addition, the PPARs control the functions of macrophages, B cells and T cells. In this review, we summarise the pathways through which the PPARs control inflammatory responses. We also discuss the potential utilisation of PPAR specific ligands in the treatment of inflammatory diseases, such as inflammatory bowel diseases, atherosclerosis, Parkinsons and Alzheimers diseases.

Keywords: peroxisome proliferator activated receptor (ppar), inflammatory diseases, immune cells, skin wound healing, bowel diseases, atherosclerosis, brain inflammation

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 4
Year: 2004
Page: [361 - 375]
Pages: 15
DOI: 10.2174/1568010042634578
Price: $58

Article Metrics

PDF: 8

Special-new-year-discount